1384984-18-2

Basic information

• Product Name: (R)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea
• Synonyms: (R)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea;VXC-486;EOS-60709;1-ethyl-3-[5-fluoro-6-[2-(2-hydroxypropan-2-yl)pyrimidin-5-yl]-4-[(2R)-oxolan-2-yl]-1H-benzimidazol-2-yl]urea
• CAS NO: 1384984-18-2
• Molecular Formula: C₂₁H₂₅FN₆O₃
• Molecular Weight: 428.4600032
• Mol File: 1384984-18-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 1.374±0.06 g/cm3(Predicted)
• PKA: 8.31±0.30(Predicted)
• CAS DataBase Reference: (R)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea(1384984-18-2)
• EPA Substance Registry System: (R)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea(1384984-18-2)

Safety Data

• Hazardous Substances Data: 1384984-18-2(Hazardous Substances Data)

Usage

General Description

The chemical "(R)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea" is a urea derivative with a complex molecular structure. It contains a urea functional group, as well as a variety of other functional groups, including an ethyl group, a fluoro group, a pyrimidine ring, a tetrahydrofuran group, and a benzoimidazole ring. This chemical likely has potential applications in the pharmaceutical industry due to its diverse structure and potential for interaction with biological systems. Further research and testing would be necessary to fully understand its properties and potential uses.

Upstream product

• 1384984-17-1 1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea 
• 59255-94-6 2-bromo-3-fluoronitrobenzene 
• 1384984-24-0 3-fluoro-2-(tetrahydrofuran-2-yl)aniline 
• 1384984-25-1 4-bromo-3-fluoro-2-(tetrahydrofuran-2-yl)aniline 
• 1384984-26-2 N-(4-bromo-3-fluoro-6-nitro-2-tetrahydrofuran-2-yl-phenyl)-2,2,2-trifluoro-acetamide 
• 1384984-27-3 4-bromo-3-fluoro-6-nitro-2-(tetrahydrofuran-2-yl)aniline 
• 1384984-28-4 2-[5-(4-amino-2-fluoro-5-nitro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol 
• 1384984-29-5 2-[5-(4,5-diamino-2-fluoro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol 
• 1319255-87-2 2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)propan-2-ol 
• 1384984-22-8 2-(2-fluoro-6-nitro-phenyl)-2,3-dihydrofuran 

Downstream Products

• 1384984-30-8 (R)-dibenzyl 2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate 

Relevant articles and documents

Second-generation antibacterial benzimidazole ureas: Discovery of a preclinical candidate with reduced metabolic liability

Compound 3 is a potent aminobenzimidazole urea with broad-spectrum Gram-positive antibacterial activity resulting from dual inhibition of bacterial gyrase (GyrB) and topoisomerase IV (ParE), and it demonstrates efficacy in rodent models of bacterial infec

SOLID FORMS OF (R)-2-(5-(2-(3-ETHYLUREIDO)-6-FLUORO-7-(TETRAHYDROFURAN-2-YL)-1H-BENZO[D]IMIDAZOL-5-YL)PYRIMIDIN-2-YL)PROPAN-2-YL DIHYDROGEN PHOSPHATE AND SALTS THEREOF

The invention relates to solid forms of the Formula (I) wherein X is -PO(OH)2, -PO(OH)O-M+, or -PO(O-)2?2M+,wherein M is a monovalent cation such as Na+, K+, Li+, or NH4+. The invention also provides pharmaceutically acceptable compositions comprising the solid form of he compound and method of using the compositions in the treatment of various disorders.

PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS

The present application is directed to compounds, intermediates and methods for preparing compounds of formula (I) or a pharmaceutically acceptable salts thereof, wherein R is H or F, and each of R3, R4, and R5 are as defined herein. The compounds of formula (I) and pharmaceutical compositions comprising said compounds and salts inhibit bacterial gyrase and/or Topo IV and are useful in treating bacterial infections.